Benign Prostatic Hyperplasic Devices Market Research Report and Outlook by 2028

The global market for benign prostatic hyperplasia (BPH) devices is projected to grow from US$ 2,078.78 million in 2021 to US$ 3,467.31 million by 2028, reflecting a compound annual growth rate (CAGR) of 7.6% from 2022 to 2028.

This growth is driven by a rise in the incidence of benign prostatic hyperplasia, increasing risk factors, and a surge in investments, funding, and grants aimed at advancing research in BPH treatments.

Benign prostatic hyperplasia is characterized by the enlargement of the prostate due to excessive cell proliferation. It is a non-cancerous condition, meaning it does not pose a fatal risk and does not spread to other parts of the body. While BPH does not increase the likelihood of developing prostate cancer, it is not considered a health concern unless it presents symptoms. By the age of 70, nearly all men will experience some degree of prostate enlargement. Factors such as aging, abdominal obesity, and a sedentary lifestyle contribute to the likelihood of developing BPH.

Companies in the benign prostatic hyperplasia device sector are heavily investing in the development of innovative surgical technologies that serve as alternatives to traditional methods. These advanced devices, equipped with cutting-edge technology, aim to provide immediate relief and minimize patient morbidity.

• January 2022: ProVerum, an EIT Health-supported startup, secured US$ 31.22 million in Series A funding from Gilde Healthcare, Lightstone Ventures, and Atlantic Bridge. The Irish company has created ProVee, a state-of-the-art treatment option for men suffering from symptomatic BPH, with plans to launch in the US and Europe using the new funding.


• June 2021: Zenflow, Inc., a medical device firm focused on minimally invasive treatments for urinary obstruction due to BPH, announced the completion of its Series B funding round, raising US$ 24 million. The round was led by Invus Opportunities, with participation from various investors including Medical Technology Venture Partners and F-Prime Capital.


• June 2021: Procept Biorobotics raised US$ 85 million to advance the AquaBeam system, a global treatment for BPH. This funding, led by Fidelity Management & Research Company, aims to leverage water-based robotic technology in prostate surgery.


• July 2019: Medeon Biodesign, a publicly traded medical device company in Taiwan, announced its investment in Prodeon, which offers a straightforward, office-based treatment for patients seeking quick relief from lower urinary tract symptoms (LUTS) due to BPH.


• April 2018: ProVerum Medical completed a US$ 4.2 million seed investment round, led by Atlantic Bridge University Fund, to initiate human trials for its BPH treatment product, which features a nitinol implant designed to dilate the prostatic urethra without altering prostate anatomy.


• February 2018: Zenflow announced a US$ 31.4 million Series A funding round to further develop its minimally invasive BPH treatment technique.

Product-Based Insights

The benign prostatic hyperplasia devices market is categorized by product type into resectoscopes, radiofrequency ablation devices, urology lasers, prostatic stents, and implants. The resectoscopes segment is anticipated to dominate the market share in 2022. However, the urology lasers segment is expected to exhibit the highest CAGR during the forecast period, driven by increasing demand from healthcare professionals and proactive product launches by market players.

Procedure Type Insights

In terms of procedure type, the market is divided into transurethral microwave therapy, transurethral resection of the prostate (TURP), transurethral needle ablation, laser surgery, urolift surgery, and others. The TURP segment is projected to hold the largest market share in 2022 and is also expected to experience the fastest growth rate from 2022 to 2028, due to its advantages such as direct visual access to the prostate and the ability to remove excess tissue immediately.

End User-Based Insights

From the perspective of end users, the market is segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospitals segment is likely to capture the largest market share in 2022. Additionally, the clinics segment is anticipated to grow at the fastest CAGR from 2022 to 2028, attributed to the increasing number of clinics offering affordable treatment options, enhanced accessibility, and reduced waiting times.

Key sources for this report include the National Center for Biotechnology Information (NCBI), National Library of Medicine, Indiana University School of Medicine, Centers for Disease Control and Prevention (CDC), Canadian Risk Factor Atlas (CRFA), World Bank, Urology Foundation, International Diabetes Federation (IDF), National Statistics Institute (INE), National Medical Device Promotion Council, International Trade Administration, and the Department of Emergency Medicine.